Maritime Fusion | $4,500,000 | (Nov 25, 2025)
Opti | $20,000,000 | (Nov 25, 2025)
Cordance Medical | $8,000,000 | (Nov 25, 2025)
Certified by Founder
Lodge
eGenesis, Inc.
start up
United States
- Cambridge, MA
- 04/09/2024
- Series B
- $191,000,000
eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene-editing techniques, eGenesis’ mission is to solve the global organ shortage crisis by developing a scalable alternative to allotransplantation.
eGenesis is reinvigorating the field of xenotransplantation by addressing the key virology and immunology hurdles that have prevented its advancement to date, and is developing commercially-viable products to save and improve the lives of patients who are waiting for an organ transplant.
- Industry Biotechnology Research
- Website https://egenesisbio.com/
- LinkedIn https://www.linkedin.com/company/egenesisbio/
AI One | $7,000,000 | (Nov 25, 2025)
Redrob | $10,000,000 | (Nov 25, 2025)
Pibit.AI | $7,000,000 | (Nov 25, 2025)
Votre | $3,750,000 | (Nov 25, 2025)
Tidalwave | $22,000,000 | (Nov 25, 2025)
Relixir | $2,000,000 | (Nov 25, 2025)
Interface | $3,500,000 | (Nov 25, 2025)
Model ML | $75,000,000 | (Nov 25, 2025)
Mirantus Health | $6,338,062 | (Nov 25, 2025)